The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1/2 gene alterations (NePtune).
 
Rana R. McKay
Consulting or Advisory Role - Astellas Medivation; AstraZeneca; AVEO; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Calithera Biosciences; Caris Life Sciences; Dendreon; Exelixis; Janssen; Lilly; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi; Seagen; Sorrento Therapeutics; Telix Pharmaceuticals; Tempus; Vividion Therapeutics
Research Funding - Bayer (Inst); Pfizer (Inst); Tempus (Inst)
 
Lin Liu
No Relationships to Disclose
 
Minya Pu
No Relationships to Disclose
 
Arlene Araneta
No Relationships to Disclose
 
Luke Wang
No Relationships to Disclose
 
Neremiah Castano
No Relationships to Disclose
 
Jennifer Gomez
No Relationships to Disclose
 
Archana Ajmera
No Relationships to Disclose
 
Huihui Ye
Stock and Other Ownership Interests - BioNTech SE; Moderna Therapeutics
Honoraria - PATHAI
Consulting or Advisory Role - Janssen Oncology; Radmetrix
Research Funding - Allogene Therapeutics
 
Roberto Pili
Consulting or Advisory Role - Amarex/Allarity
Research Funding - Bristol-Myers Squibb (Inst); Clinigen Group (Inst); Merck (Inst); Syndax (Inst)
 
Karie Runcie
Consulting or Advisory Role - Johnson & Johnson/Janssen
 
Deaglan Joseph McHugh
Honoraria - OncLive
Consulting or Advisory Role - Progenics
 
Kenneth Offit
Patents, Royalties, Other Intellectual Property - Patent pending on therapeutic applications of targeting ERCC3 mutations in cancer. Diagnosis & treatment of ercc3-mutant cancer US20210137850A1
Other Relationship - AnaNeo Therapeutics
 
Channing Judith Paller
Consulting or Advisory Role - AstraZeneca; Dendreon; Exelixis; Omnitura
Research Funding - Lilly (Inst)
Travel, Accommodations, Expenses - Bayer; Bayer
 
Naomi B. Haas
Consulting or Advisory Role - AVEO; Calithera Biosciences; Eisai; Exelixis; Merck Sharp & Dohme; Pfizer; Roche/Genentech
Expert Testimony - Lilly (I)
 
Juan Javier-Desloges
No Relationships to Disclose
 
Christopher J. Kane
No Relationships to Disclose
 
Tyler M Seibert
Stock and Other Ownership Interests - CorTechs Labs
Honoraria - Varian Medical Systems
Consulting or Advisory Role - CorTechs Labs
Research Funding - GE Healthcare (Inst)
 
Aditya Bagrodia
Consulting or Advisory Role - Veracyte